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Group B streptococcus (GBS; Streptococcus agalac-
tiae) is a Gram-positive encapsulated commensal 
bacterium of the human intestine that is also pres-
ent in the vagina of 15–30% of healthy women. 
In neonates, it may turn into a deadly pathogen, 
and it is the leading cause of neonatal pneumonia, 
septicaemia, and meningitis (Edwards and Baker, 
2005). Despite early antimicrobial treatment and 
improvement in neonatal intensive care, up to 
10% of neonatal GBS infections are lethal, and 
25–35% of surviving infants with meningitis 
experience permanent neurological sequelae 
(Edwards  and  Baker,  2005).  GBS  is  also  a   
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Streptococcus agalactiae (group B streptococcus; GBS) is a normal constituent of the 
intestinal microflora and the major cause of human neonatal meningitis. A single clone, 
GBS ST-17, is strongly associated with a deadly form of the infection called late-onset 
disease (LOD), which is characterized by meningitis in infants after the first week of life. 
The pathophysiology of LOD remains poorly understood, but our epidemiological and histo-
pathological results point to an oral route of infection. Here, we identify a novel ST-17–
specific surface-anchored protein that we call hypervirulent GBS adhesin (HvgA), and 
demonstrate that its expression is required for GBS hypervirulence. GBS strains that express 
HvgA adhered more efficiently to intestinal epithelial cells, choroid plexus epithelial cells, 
and microvascular endothelial cells that constitute the blood–brain barrier (BBB), than did 
strains that do not express HvgA. Heterologous expression of HvgA in nonadhesive bacteria 
conferred the ability to adhere to intestinal barrier and BBB-constituting cells. In orally 
inoculated mice, HvgA was required for intestinal colonization and translocation across the 
intestinal barrier and the BBB, leading to meningitis. In conclusion, HvgA is a critical 
virulence trait of GBS in the neonatal context and stands as a promising target for the 
development of novel diagnostic and antibacterial strategies.
© 2010 Tazi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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We show that this protein which we have called hypervirulent 
GBS adhesin (HvgA) mediates GBS neonatal intestinal coloniz-
ation and crossing of the intestinal and blood–brain barriers, 
leading to meningitis, which are key features of LOD.
RESULTS AND DISCUSSION
Epidemiological evidence that the ST-17 hypervirulent GBS 
clone is associated with LOD and neonatal meningitis
We first analyzed 651 GBS isolates referred to the French na-
tional reference center for streptococci between 2006 and 
2009 from consecutive cases of invasive infection in neonates 
(meningitis, n = 138; bacteremia, n = 166) and in adults (men-
ingitis, n = 16; bacteremia, n = 331). Serotype III accounts for 
86.2% of strains isolated from cases of neonatal meningitis 
and 60.8% of neonatal bacteremia, but only 25.7% of bacte-
remia in adults (Table I). Serotype III is significantly associ-
ated with meningitis during EOD (79.3%; P < 0.0001) and 
LOD (88%; P < 0.0001; Table I). Moreover, the serotype III 
ST-17 clone is significantly associated with meningitis during 
EOD (79.3%; P < 0.0001) and LOD (82.6%; P < 0.0001), 
and with bacteremia during LOD (78.1%; P < 0.0001; Table I). 
In contrast, the ST-17 clone represents <12% of isolates from 
adult patients with bacteremia (Table I). Together, these results 
obtained from a total of 651 clinical strains demonstrate that 
ST-17 GBS strains account for >80% of neonatal meningitis, 
strongly suggesting an enhanced virulence of the ST-17 clonal 
complex in the neonatal context. These epidemiological ob-
servations thus prompted us to search for specific virulence 
factors of the ST-17 clone that may account for its apparent 
higher pathogenicity in neonates, its close association with 
LOD, and its meningeal tropism.
Histopathological study of a fatal case  
of ST-17–associated LOD
A term female infant (gestational age, 39 wk; birth weight, 
3,140 g) was born by spontaneous vaginal delivery without 
complication. Maternal vaginal swab at 37 wk of gestation 
was negative for GBS. There was no premature membrane 
rupture and neither skin nor rectal swab of the neonate was 
made at delivery. The mother and her breastfed baby were 
discharged on day 4. On day 14 of life, the neonate developed 
muscular hypotonia, poor suckling, hyperexcitability, and   
fever. Cerebrospinal fluid and blood cultures were positive for 
GBS, which was later shown to belong to serotype III and 
clonal complex ST-17. Breast milk was not cultivated. Despite 
adequate antimicrobial treatment associating amoxicillin, cef-
triaxone, and gentamicin, she died 8 h later and an autopsy 
was performed. Cultures of stool, blood, and cerebrospinal fluid, 
as well as colonic and brain autopsic tissue samples, were all 
positive for GBS. Immunohistochemistry of paraffin-embedded 
gut tissue samples led to the detection of GBS associated with 
the intestinal tissue and inside the lamina propria (Fig. 1, a and b). 
GBS also heavily infected meningeal tissues, with intense in-
flammation indicated by the massive recruitment of poly-
morphonuclear cells (Fig. 1, c and d). GBS was also observed 
to be tightly associated with brain microvessel endothelial 
significant cause of morbidity and mortality in nonpregnant 
adults, particularly those with underlying diseases and the   
elderly (Phares et al., 2008).
Two distinct GBS-associated clinical syndromes, referred   
to as early-onset disease (EOD) and late-onset disease (LOD) 
have been recognized in neonates in their first week of life (age 
0–6 d) and after (age 7–89 d), respectively (Edwards and Baker, 
2005). Although intrapartum antibioprophylaxis for parturient 
women at risk for GBS infection has markedly decreased the 
incidence of EOD, it did not change that of LOD (Poyart et al., 
2008; CDC, 2009). Epidemiological data collected worldwide 
have shown that a substantial proportion of EOD and the ma-
jority of LOD are associated with capsular serotype III (Lin et al., 
2006; Gherardi et al., 2007; Phares et al., 2008; Poyart et al., 
2008; CDC, 2009). Strains of serotype III contain a limited 
number of clonal complexes, defined by multilocus sequence 
typing. Among them, the ST-17 sequence type is strongly associ-
ated with neonatal meningitis and was therefore designated as 
“the hypervirulent clone,” despite the absence of experimental 
data to support this assertion (Musser et al., 1989; Jones et al., 
2003, 2006; Brochet et al., 2006; Lamy et al., 2006; Bohnsack 
et al., 2008; Poyart et al., 2008; Manning et al., 2009).
For EOD, the mode of transmission in newborns is thought 
to be vertical, by inhalation of GBS-contaminated amniotic or 
vaginal fluid during parturition, followed by bacterial trans-
location across the respiratory epithelium and subsequent sys-
temic infection (Edwards and Baker, 2005). In contrast, for 
LOD, the mode of transmission and the infection route remain 
elusive, although mother-to-child transmission might also be 
involved. A plausible scenario would involve early intestinal 
colonization by GBS that would lead in the first days of life to 
its intraluminal intestinal multiplication, translocation across 
the intestinal epithelium, and access to the bloodstream.   
Indeed, an intestinal portal of entry for LOD is supported by 
several lines of evidence: (a) 60 and 40% of the neonates asymp-
tomatically colonized with GBS at birth remain positive for 
bacteria at the rectal level at 4 and 12 wk of life, respectively 
(Weindling et al., 1981); and (b) a longitudinal study of GBS 
vaginal and rectal colonization in women during and after 
pregnancy has revealed that carriers are usually colonized for 
up to 2 yr by a single clone, which is also frequently found in 
newborn feces for up to 1 yr (Hansen et al., 2004).
Once translocated in the bloodstream, GBS has the ability 
to cross the blood–brain barrier (BBB) and cause meningitis. 
Several virulence factors contribute to the pathogenesis of GBS 
meningitis in animal models, but nearly all of them are in-
volved in the septicemia phase of the infection, but not in GBS 
adhesion to and crossing of the BBB (Maisey et al., 2008). One 
exception is Srr-1, a recently characterized surface glycoprotein 
that promotes adhesion to and invasion of human brain micro-
vascular endothelial cells and contributes to BBB crossing in 
mice (van Sorge et al., 2009). This illustrates that more studies 
are needed to identify virulence factors of GBS, especially in 
regard to its meningeal tropism and its ability to trigger LOD.
Here, we have identified a novel ST-17–specific surface-
anchored protein, which is highly prevalent in cases of LOD. JEM VOL. 207, October 25, 2010  2315
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HvgA is an ST-17–specific surface-anchored protein  
that is overexpressed in vivo
We first analyzed whether the ST-17 clone expresses specific 
surface-exposed molecules that could account for enhanced 
adhesive properties. The comparative analysis of GBS whole-
genome sequences has pinpointed several genes encoding 
surface components specific to the ST-17 clone (Tettelin et al., 
2005; Brochet et al., 2006). In partic-
ular, we have identified mosaic variants 
at a single genomic locus (Lamy et al., 
2006) encoding a cell wall–anchored 
protein, with two main variants dis-
playing 38% overall amino acid iden-
tity, namely Gbs2018A, which is also 
referred to as BibA (Santi et al., 2007), 
and Gbs2018C, which we have shown 
to be strictly specific to the “hyper-
virulent” ST-17 clone (Lamy et al., 
2006). These genes have conserved reg-
ulatory  regions  and  encode  proteins 
with conserved N- and C-terminal 
parts, but a distinct central core. Indeed, 
comparison of the nucleotide sequences 
of the two loci has revealed that only 
the 5 and 3 ends of the two genes 
are highly conserved, displaying >90% 
sequence  identity,  whereas  their  in-
ternal parts display low level (50–60%) 
cells and choroid plexus epithelial cells, which constitute the 
blood–brain parenchyma and blood–cerebrospinal fluid bar-
riers, respectively (Fig. 1, e–l). These bacteriological and histo-
pathological analyses of this fatal case of LOD are consistent 
with the hypothesis that LOD results from the ability of GBS 
ST-17 to efficiently colonize the intestine, cross the intestinal 
barrier, and cross the BBB.
Table I.  Serotype and ST-17 distribution of 651 GBS strains isolated from neonatal and non-pregnant adult invasive infections 
in France between 2006 and 2009
Type of infection Serotype no. ST-17 no. 
Ia Ib II III IV V Total
% %
Neonatal meningitis 12 (8.7) 4 (2.9) 0 119 (86.2) 0 3 (2.1) 138 (100) 113 (81.9)
  EOD (≤6 d) 6 (20.7) 0 0 23 (79.3) 0 0 29 (100) 23 (79.3)
  LOD (≥7–89 d) 6 (5.5) 4 (3.7) 0 96 (88.1) 0 3 (2.7) 109 (100) 90 (82.6)
Neonatal bacteremia 34 (20.5) 5 (3) 6 (3.6) 101 (60.8) 3 (1.8) 17 (10.2) 166 (100) 89 (53.6)
  EOD (≤6 d) 27 (29) 3 (3.2) 5 (5.4) 41 (44.1) 2 (2.2) 15 (16.1) 93 (100) 32 (34.4)
  LOD (≥7–89 d) 7 (9.6) 2 (2.7) 1 (1.4) 60 (82.2) 1 (1.4) 2 (2.7) 73 (100) 57 (78.1)
Adult bacteremia 71 (21.4) 36 (10.3) 37 (11.2) 85 (25.7) 17 (5.1) 85 (25.7) 331 (100) 37 (11.2)
Adult meningitis 4 (25) 2 (12.5) 1 (6.25) 8 (50) 0 1 (6.25) 16 (100) 5 (31.3)
Figure 1.  ST-17 GBS crossing of the 
intestinal and BBBs in a fatal case of  
human neonatal LOD with meningitis. 
Immunohistological study of the intestine and 
the CNS of a fatal case of ST-17 LOD. Bacteria 
were labeled with a specific polyclonal anti-
body to GBS and appear in reddish brown. 
Sections were counterstained with hematoxy-
lin. GBS is present in the intestine (a and b), in 
meninges (c and d), in brain microvessels (e–j), 
as well as in choroid plexuses (k and l).2316 Hypervirulence of ST-17 group B streptococcus | Tazi et al.
released in the cul-
ture supernatant of 
the  srtA  mutant, 
but not of the WT 
GBS BM110. Col-
lectively,  these  re-
sults  demonstrate 
that HvgA is a protein anchored to the cell wall by sortase A. 
Flow cytometry and immunofluorescence microscopy con-
firmed surface expression of HvgA in GBS WT ST-17 (Fig. 2, 
c and d). To investigate HvgA expression in vivo, quantita-
tive RT-PCR (qRT-PCR) on mRNAs extracted from 
cecal, blood, and brain samples of orally or i.v. infected mice 
(see Materials and methods) were performed and demonstrated 
that hvgA in vivo expression, relative to that of rpoB, is two- 
to fourfold higher than in vitro (Fig. 2 e). Moreover, in total 
or no significant (<20%) sequence identity (Fig. 2 a). We 
thus investigated the contribution of Gbs2018C (hereafter 
named HvgA for hypervirulent GBS adhesin) to GBS neona-
tal infection using in vitro and in vivo approaches, with the 
hypothesis that it might be responsible for enhanced viru-
lence capacities of the ST-17 clone. We first demonstrated, 
by immunoblotting using specific anti-HvgA antibodies that 
HvgA in GBS BM110, a prototype ST-17 strain, harbors an 
LPXTG motif that anchors it to the cell wall in a sortase A–
dependent manner. As shown in Fig. 2 b, a band correspond-
ing to HvgA was detected in cell wall extracts of the WT 
strain, but not of an isogenic srtA mutant strain. Analysis of 
the corresponding culture supernatant demonstrated that this 
protein is not secreted in the medium by the WT strain   
(unpublished data). Moreover, after incubation in SDS at 
high temperature (10 min at 100°C), HvgA is massively   
Figure 2.  HvgA is a cell surface protein 
of GBS ST-17. (a) Structure of the bibA/hvgA 
locus in GBS strains NEM316 (WT ST-23) and 
BM110 (WT ST-17). Comparison of the nucleo-
tide sequences of the two loci revealed that 
only the 5 and 3 ends of the two genes were 
highly conserved, displaying >90% sequence 
identity, whereas their internal parts displayed 
low-level (50–60%) or no significant (<20%) 
sequence identity. The positions of the prim-
ers used to carry out in-frame deletion within 
bibA and hvgA (O1-O2 plus O3-O4), or to 
clone hvgA (O5-O6), are depicted by small 
vertical arrows. P, promoter; ter, terminator. 
The CovR binding site is depicted by a blue 
box. The pairwise local alignment was per-
formed with LFasta and visualize with Laln-
View (http://pbil.univ-lyon1.fr/lfasta.php).  
(b) Western-blot analysis of cell wall–anchored 
proteins of GBS with anti-HvgA antiserum. 
Surface proteins extracted by mutanolysin 
(CW) or hot SDS treatment from GBS BM110 
WT ST-17, its hvgA and srtA mutants, and 
the complemented hvgA mutant were sepa-
rated on 10% tris-glycine SDS-PAGE gels and 
immunoblotted with a specific anti-HvgA 
antiserum (protein fragment 30–216). HvgA 
corresponds to 2 ng of purified recombinant 
protein extracted from E. coli. (c) Cell surface 
exposure of HvgA in GBS WT ST-17. Immuno-
fluorescence analysis was performed with 
rabbit polyclonal anti-HvgA antibodies (pro-
tein fragment 30–216) revealed with an anti-
IgG coupled to Alexa Fluor 488. Bars, 10 µm. 
(d) Flow cytometry analysis of GBS WT ST-17 
and its hvgA mutant, GBS WT ST-23 and its 
bibA mutant incubated with a polyclonal 
anti-HvgA, or anti-BibA (protein fragment 
34–295) antibodies and stained with a sec-
ondary Alexa Fluor 488–conjugated anti–
rabbit IgG antibody (solid line) or with 
secondary only (dotted line). (e) qRT-PCR 
analysis of hvgA in GBS BM110 in vitro and  
in vivo. Values are presented as a ratio of 
expression in blood, brain, and cecum of in-
fected BALB/c mice relative to expression in 
TH broth medium. Results shown are repre-
sentative of two independent experiments 
performed in triplicate. Error bars are the SD 
of the depicted variable. *, P < 0.05.JEM VOL. 207, October 25, 2010  2317
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and  BibA,  respectively  (Table  S1).   
Whereas  both  strains  adhere  simi-
larly  to  A549  pulmonary  epithelial 
cells, the ST-17 strain adheres signifi-
cantly more efficiently to the intesti-
nal  epithelial  Caco-2  cell  line,  the 
BBB-constituting cells hCMEC/D3, 
brain primary microvessel endothelial 
cells  (MVECs),  and  choroid  plexus 
epithelial  cells  (CPECs;  Fig.  3  a).   
The significance of these results was 
broadened by the study of 20 randomly 
picked invasive GBS neonatal isolates 
of ST-17 type (n = 10) or non–ST-17 
type (n = 10; strain characteristics de-
scribed in Table S2). As seen for the prototype strains, com-
parative cell binding assays showed that ST-17 isolates adhere 
significantly  more  to  Caco-2  and  hCMEC/D3  cells  than 
non–ST-17 isolates, but not to A549 cells (Fig. 3 b), thereby 
suggesting that bacteria expressing HvgA could display a spe-
cific enhanced capacity to adhere to cells of the intestinal and 
blood–brain barriers. To further investigate whether HvgA is 
the adhesin involved in the ST-17 interaction with intestinal 
and blood–brain barriers constituting cells, a GBS BM110hvgA 
deletion mutant was constructed (Fig. 1 a and Tables S1 and S3). 
As expected, HvgA was not expressed in this mutant and not 
detected at the bacterial cell surface (Fig. 2, b–d). The growth 
characteristics and the viability of the mutant in various culture 
media (Todd-Hewitt, RPMI, or DME complemented with 
10% human serum), in total human blood, as well as the 
morphological characteristics and the aggregative properties 
human blood, hvgA is similarly overexpressed by threefold 
relative to standard culture medium (unpublished data). As for 
gbs2018A/bibA (Lamy et al., 2004; Mereghetti et al., 2008), 
hvgA transcription is up-regulated 85-fold in a 2-component 
regulatory system CovSR mutant (BM110covR; unpublished 
data). Together, these data show that HvgA is expressed on 
GBS ST-17 surface and that its expression is up-regulated in 
in vivo conditions.
HvgA promotes specific GBS adhesion to epithelial  
and endothelial cells
Because these data pointed to HvgA as a potential ST-17–
specific determinant conferring selective adhesive properties 
to GBS, we compared the adhesion to different cell types of 
two reference strains, BM110 serotype III ST-17 (WT ST-17) 
and NEM316 serotype III ST-23 (WT ST-23) expressing HvgA 
Figure 3.  HvgA promotes specific hyper-
adhesion to epithelial and endothelial 
cells. (a and b) Comparison of the adhesive 
properties of ST-17 and non–ST-17 GBS 
strains. Cells were cultured for 1 h with bacte-
ria, washed three times, and lysed, and CFUs 
were enumerated after plating on TH agar 
plates. Values are expressed as the percent-
age of adhesion relative to the inoculum.  
(c and d) Adhesion of GBS BM110 WT (ST-17) 
and hvgA mutant to various cell lines, pri-
mary choroid plexus epithelial cells, and brain 
microvessel endothelial cells. Adhesion assays 
were conducted as described in a and b. 
Streptococci were labeled with a pAb-GBS 
(green), nuclei were labeled with Dapi (blue) 
and ZO1 with an anti-ZO1 antibody, and  
F-actin was labeled with phalloidin (red). Bar, 
20 µm. Throughout this figure, results are repre-
sentative of at least three independent experi-
ments performed in triplicate. Error bars 
represent the SD. Asterisks indicate significant 
differences relative to BM110 WT or GBS ST-17 
strains, as assessed by the Mann-Whitney  
test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).  
NS, a nonsignificant difference.2318 Hypervirulence of ST-17 group B streptococcus | Tazi et al.
intestinal  barrier.  To  test  this  hypothesis,  we  used  inbred 
BALB/c mice, as we observed that they displayed higher   
susceptibility than outbred Swiss mice upon oral infection. 
Moreover, we also observed that 4–5-wk-old mice were more 
resistant upon oral challenge than preweaning (15–21-d-old) 
BALB/c mice. We therefore inoculated orally preweaning 
(15–21-d-old) BALB/c mice with 1010 or 2 × 109 CFUs. 
Their mortality rate 12 h after infection was significantly de-
creased when inoculated with the hvgA mutant as compared   
to inoculation with the WT strain (Fig. 5 g). Furthermore, 8 h   
of the streptococcal chains, were similar to that of the parental 
WT strain (unpublished data). We then compared the adhe-
sion properties of the hvgA mutant to its isogenic parent, 
and showed that it exhibited a significantly reduced adhesion 
to a series of epithelial and endothelial human cell lines and 
rodent primary cells (Fig. 3, c and d). The direct involvement 
of HvgA in bacterial adhesion to cells was further established. 
Indeed, trans-complementation with a plasmid-driving hvgA 
expression  (PhvgA)  restored  BM110hvgA  strain  adhesive 
properties to a level similar to that of the WT strain (Fig. 4 a). 
Furthermore, introduction of PhvgA in Lactococcus lactis enabled 
HvgA expression on the lactococcal surface, as assessed by im-
munofluorescence microscopy and flow cytometry(Fig. 4,   
b and c). Trans-complemented L. lactis strains were used in   
assays as described for GBS to investigate HvgA-mediated 
adhesion: a strain expressing HvgA adhered significantly more 
efficiently to Caco-2 and hCMEC/D3 cells than L. lactis 
with a vector without insert and L. lactis expressing BibA 
(Fig. 4 d). The nonpathogenic species L. lactis is intrinsically 
nonadhesive, yet heterologous expression of HvgA in L. lactis 
confers a clear adhesive phenotype. Moreover, a bibA mu-
tant expressing HvgA adhered 10-fold more efficiently to 
hCMEC/D3 cells, as compared with the WT non–ST-17 
(NEM316) strain (Fig. 4 e). Thus, replacement of bibA by 
hvgA in GBS NEM316 confers an ST-17 adhesion pheno-
type to this non–ST-17 strain, and establishes the specific ad-
hesive property conferred upon HvgA expression.
HvgA is critical for GBS intestinal colonization  
and translocation across the intestinal barrier
These in vitro data argued for a key contribution of HvgA in 
the ability of ST-17 GBS to adhere to cells constituting the 
intestinal and blood–brain barriers, which are targeted during 
LOD. We investigated this issue in the in vivo context and 
used mouse models of GBS infection closely mimicking the 
pathology observed in the human neonate. We first moni-
tored  fecal  shedding  after  oral  inoculation  (1010  CFUs)  of 
Swiss female mice (3–4 wk old) with WT ST-17 (BM110), its 
isogenic mutant hvgA or WT ST-23 (NEM316), to assess 
their respective ability to colonize the intestine. Quantifica-
tion of GBS in feces showed that: a WT ST-17 strain estab-
lishes in the intestine more than one order of magnitude better 
than a non–ST-17 strain (Fig. 5 a), HvgA strongly contributes 
to this ST-17–specific phenotype (Fig. 5 b), and the non–ST-17 
allelic variant BibA has no significant impact on gut colonization 
(Fig. 5 c). Ex vivo experiments with cecal tissue explants also 
demonstrated an HvgA-mediated bacterial association to the 
cecal epithelium (Fig. 5 d). In addition, competition experi-
ments for intestinal colonization in which 5 × 109 CFUs of 
each strain were simultaneously inoculated indicated that within 
<1 wk, ST-17 WT totally out-competes a non–ST-17 WT 
strain (Fig. 5 e), as well as an isogenic hvgA mutant (Fig. 5 f). 
Together, these results demonstrate that HvgA confers a selec-
tive advantage at this initial step of infection.
We next addressed whether HvgA could provide the   
ST-17 strain with an enhanced ability to translocate across the 
Figure 4.  HvgA is necessary and sufficient to promote adhesion of 
GBS and L. lactis to epithelial and endothelial cells. (a) Comparison 
of the adhesive properties of WT ST-17 GBS and hvgA mutant or com-
plemented strain on intestinal epithelial (Caco-2) and brain microvascular 
endothelial (hCMEC/D3) cell lines. Adhesion assays were conducted as 
described for Fig. 3, performed in triplicate, and repeated independently at 
least 3 times; graphs show cumulative data from all experiments. Error 
bars represent the SD. ***, Mann-Whitney test (P < 0.005), relative to WT 
ST-17. (b and c) Expression of HvgA in L. lactis. (b) Immunofluorescence 
analysis was performed with rabbit polyclonal anti-HvgA antibodies (pro-
tein fragment 30–216) revealed with an anti-IgG coupled to Alexa Fluor 
488. Bars, 10 µm. (c) Flow cytometry analysis of L. lactis expressing HvgA 
incubated with a polyclonal anti-HvgA antibody and stained with an  
Alexa Fluor 488–conjugated anti–rabbit IgG antibody (black line histogram). 
(d) Comparison of adhesive properties of L. lactis and HvgA- or BibA-
expressing strains on Caco-2 and hCMEC/D3 cell lines. Error bars repre-
sent the SD. *, Mann-Whitney test (P < 0.05), relative to L. lactis + vector. 
(e) hvgA confers to WT non–ST-17 and ST-17 adhesion phenotype. Com-
parison of adhesive properties of WT non–ST-17 and bibA mutant or 
complemented strains expressing BibA or HvgA on brain microvascular 
endothelial cell line hCMEC/D3. Experiments were performed in triplicate 
and repeated independently at least three times; graphs show cumulative 
data from all experiments. **, Mann-Whitney test (P < 0.01), relative to WT 
non ST-17.JEM VOL. 207, October 25, 2010  2319
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microscopy (Fig. S2). In mice with the highest WT-ST17 bac-
terial load (5 × 107 CFUs) in the brain, GBS were observed 
adhering to the inner meningeal envelopes (pia matter, Fig. S2 a) 
in the brain microvessel (Fig. S2 b), in the brain parenchyma 
(Fig. S2 c), or in the choroid plexuses (Fig. S2 d). In contrast, 
no bacterium was observed in mice infected with the hvgA 
mutant. To focus specifically on the crossing of the BBB and 
bypass the HvgA phenotype at the BALB/c intestinal barrier 
level, we developed a CNS infection model in which pre-
weaning 3 wk mice were infected i.v. every 12 h with a rela-
tively low inoculum (5 × 106 CFUs) to avoid unspecific BBB 
opening caused by the massive systemic inflammation trig-
gered by high bacterial loads, but to instead mimic blood-
borne neonatal meningitis. Monitoring of bacterial loads in 
the blood and the CNS showed that whereas WT ST-17 and 
its hvgA isogenic mutant induce a similar level of bacteremia 
48 h after i.v. inoculation (Fig. 6 c), hvgA is significantly im-
paired in its ability to invade the CNS (Fig. 6 d). In agreement 
with these quantitative data, real-time imaging of biolumines-
cent bacteria along the infectious process revealed a marked 
bioluminescence emission in the head of animals infected 
with WT ST-17 (4/4 animals), which was detectable 20 h after 
infection and is visible until the death of the animal, whereas 
merely no signal was detected in mice infected with the 
hvgA mutant (Fig. 6 e). Neuropathological analysis of in-
fected animals 48 h after i.v. inoculation disclosed an intense 
after oral inoculation of 4–5-wk-old BALB/c mice with 1010 
or 109, no mortality was observed. But here again, the WT 
ST-17 strain adhered to and invaded the cecal tissue more 
significantly than the hvgA mutant (Fig. 5 h and Fig. S1 a), 
indicating a key role for HvgA in GBS ST-17 ability to cross 
the intestinal barrier. Moreover, in germ-free animals infected 
with WT GBS ST-17, bacteria could be observed adhering 
to the enterocytes and in the lamina propria (Fig. S1, b-e), 
similar to what was observed in the human previously de-
scribed LOD case (Fig. 1, a and b)
HvgA contributes to GBS crossing of the blood–brain barrier 
and the onset of meningitis
We next analyzed HvgA contribution to central nervous system 
(CNS) invasion. A role for HvgA in this process was supported 
by results obtained with orally inoculated animals: 15–21-d-old 
BALB/c mice infected with the WT GBS-ST17 strain have 
significantly higher bacterial counts in the brain than the 
mice infected with the hvgA mutant at the experiment end-
point (Fig. 6, a and b). Moreover, animals that died in the 
meantime are those for which bacterial counts in the brain 
are the highest (Fig. 6 a), arguing for a causal relationship 
between HvgA expression and GBS ST-17 ability to reach 
the CNS after oral inoculation. To investigate the onset of 
meningitis in these orally inoculated animals, their brains 
were  examined  by  immunohistochemistry  and  confocal   
Figure 5.  HvgA enables GBS persistent 
intestinal colonization and promotes  
its crossing of the intestinal barrier.  
(a–c) Groups (n = 6) of 3–4-wk-old Swiss 
female mice were infected orally with 1010 CFUs 
WT GBS or mutant strains, and fecal shedding 
was assessed 3, 7, and 14 d after inoculation 
by CFUs enumeration. Values represent fecal 
shedding of the six mice in a cage. (d) Infec-
tion of Swiss mice (n = 4) ligated cecum with 
1010 GBS WT ST-17 or hvgA mutant strain. 
Bacteria were recovered 1 h after infection. 
Values are expressed as the percentage  
of adhesion relative to the inoculum.  
(e and f) Competition assays between WT ST-17 
(BM110) and WT non–ST-17 (NEM316) or 
hvgA BM110 mutant. 3–4-wk-old Swiss 
mice (n = 6) were infected orally with a 1:1 
mixture of the two strains (total dose 1010 
CFUs). Bacteria were enumerated from the 
feces collected 3, 7, and 10 d after infection. 
(g) Mortality rate 12 h after infection of  
15–21 d old BALB/c mice (n = 10) infected orally 
with the WT ST-17 or hvgA mutant strains. 
(h) Groups of 4-wk-old BALB/c mice (n = 10) 
were inoculated orally with 1010 CFUs WT ST-17 or hvgA mutant strains. 8 h after infection, animals were sacrificed. Cecum were collected and divided 
longitudinally in two parts. One half was directly homogenized: extra- and intratissular bacteria associated with the cecum were enumerated (no genta.). 
The second half was incubated for 3 h in DMEM containing 250 µg/ml gentamicin to kill extratissular bacteria and homogenized. Intratissular invading 
bacteria were then enumerated (genta.). Animal experiments represented in this figure were repeated at least two times and groups of mice contained at 
least five animals. Error bars represent the SD of depicted variable performed in triplicate. Asterisks indicate significant differences as assessed by the 
Mann-Whitney test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).2320 Hypervirulence of ST-17 group B streptococcus | Tazi et al.
associated with ST-17 GBS isolates: (1) their close 
association with LOD, which can now be linked 
to HvgA-mediated intestinal colonization and 
subsequent crossing of the intestinal barrier, and 
(2) their close association with meningitis, which 
can now be linked to the HvgA-mediated cross-
ing of the BBB. This study definitely establishes 
the  hypervirulence  of  the  ST-17  GBS  clone 
and links it to enhanced intestinal colonization 
and barrier breaching potentials. Importantly, it 
illustrates how a microbial factor implicated in 
bacterial intestinal colonization can behave as a 
specific virulence factor in the neonatal con-
text, at a time when the intestinal microflora is 
not yet established and cannot exerts its buffer-
ing effect on potential pathogenic bacteria such as GBS. Given 
the burden of ST-17–associated LOD and neonatal meningi-
tis (Poyart et al., 2008; CDC, 2009), hvgA and its gene product are 
now promising targets for developing diagnostic tools (Lamy 
et al., 2006) and vaccines (Santi et al., 2009), respectively.
MATERIAL AND METHODS
Bacterial strains, genetic constructions, and growth conditions. The 
main characteristics of bacterial strains and plasmids used in this study are 
listed in Table S1. GBS NEM316, capsular serotype III, and MLST type ST 
23, and GBS BM110, capsular serotype III, and MLST sequence type ST-17 
are well-characterized isolates from human with invasive infections. GBS 
clinical strains from invasive infection were collected by the National Refer-
ence  Center  for  Streptococci  from  2006  and  2009.  GBS  mutants  were   
constructed  by  in-frame  deletions  in  bibA  (GBS  NEM316),  hvgA  (GBS 
BM110), and srtA (GBS BM110), as previously described (Dramsi et al., 2006) 
WT ST-17 streptococcal infection of choroid plexuses and 
meninges (Fig. 6, f, g, i, and k), as well as in brain microvessels 
and the surrounding brain parenchyma (Fig. 6, h and k), a result 
matching our observations in the human LOD case associated 
with ST-17 GBS (Fig. 1, c–l). Together, these in vivo results dem-
onstrate HvgA contribution in ST-17 access to the CNS, a 
result that corroborates our in vitro data (Fig. 3, c and d).
Conclusions
Using complementary approaches, we have uncovered a key 
determinant  of  the  pathophysiology  of  ST-17–associated 
LOD. We have identified an ST-17–specific surface-expressed 
protein, HvgA, and demonstrated that it is a major determi-
nant of ST-17 hypervirulence in neonates. Our results pro-
vide a rational explanation for the two main characteristics 
Figure 6.  HvgA enables GBS crossing of the BBBs. 
(a and b) Groups of 15–21 d old BALB/c mice (n > 8) 
were inoculated orally with 109 (a) or 5 × 108 CFUs (b) WT 
ST-17 or hvgA mutant strain and brain invasion was 
assessed 12-h after inoculation by CFUs enumeration.  
(c and d) Groups of 3–4-wk-old BALB/c mice (n > 8) were 
infected by repeated i.v. injections of 5 × 106 CFUs every 
12 h and sacrificed at 48 h, and bacteria enumerated in 
blood (c) and brain (d). Data shown are the results of 
three independent experiments. (e) Real-time imaging of 
CNS infection. Groups of BALB/c mice (n = 4) were in-
fected i.v. with 108 CFUs every 12 h. Bioluminescence was 
assessed every 12 h (the images shown correspond to 
the 36 h after injection time point). (f–h) Histopathologi-
cal examination (Gram staining) of CNS tissue samples 
from WT-ST-17 infected mice reveals Gram-positive cocci 
in the meninges (f), in the choroid plexuses (g), in brain 
microvessel endothelial cells and the surrounding brain 
parenchyma (h). (i–k) Immunofluorescence staining of 
brain sections obtained from animals infected with the 
WT ST-17 in d, showing infection of meninges (i), sub-
meningeal space (j), and brain microvessel endothelial 
cells (k). Bars: (f–h) 25 µm; (i–5) 20 µm. All experiments 
were repeated at least three times. NS, not significant. 
Asterisks indicate significant differences as assessed  
by the Mann-Whitney test (*, P < 0.05; **, P < 0.01;  
***, P < 0.001).JEM VOL. 207, October 25, 2010  2321
Brief Definitive Report
injected intragastrically. At the indicated times, cecum were collected, rinsed 
in DME, and divided in two parts longitudinally. One half was directly ho-
mogenized in PBS with a tissue homogenizer. The second half was incu-
bated for 3 h in DME containing 250 µg/ml21 gentamicin to determine 
bacterial invasion, rinsed, and homogenized. Serial dilutions were plated on 
selective medium (Granada) for CFU counts. For cecum-ligated loop ex-
periments, animals were anesthetized. The whole cecums were closed at 
both ends with surgical sutures. 200 µl of the adequate bacterial dilution was 
injected in the lumen. 1 h after infection, the mice were sacrificed; the cecum-
ligated loops were excised and opened longitudinally. For competitive assay, 
both WT and isogenic mutants were mixed in a 1:1 ratio oral infection ex-
periments. At the indicated times, stools were collected and serial dilutions 
were plated on selective medium. i.v. infections were performed by i.v. in-
jection every 12 h for 36 h. All of the procedures were in agreement with 
the guidelines of the European Commission for the handling of laboratory 
animals, directive 86/609/EEC (http://ec.europa.eu/environment/chemicals/
lab_animals/home_en.htm) and were approved by the Animal Care and Use 
Committees of the Institut Pasteur.
Bioluminescence  real-time  imaging. GBS WT-ST17 strain and the 
hvgA isogenic mutant were made bioluminescent after introduction plas-
mid pTCVlux by electroporation (Table S1). After i.v. infection, BALB/c 
mice  bioluminescence  was  monitored  each  day,  as  previously  described 
(Disson et al., 2009). 12 h before infection and every 12 h during the infec-
tion, animals were treated with erythromycin (20 mg/kg21).
Tissue labeling. Thin sections, thick sections, and whole-mount tissue la-
beling were performed as previously described (Disson et al., 2009). Acquisi-
tion of images was realized with an upright confocal microscope (Carl Zeiss, 
Inc.), using a 40× water immersion objective for the whole-mount tissue or 
an oil immersion objective for the thick section labeling. Reconstructions 
were realized using Imaris software.
Online supplemental material. Fig. S1 shows the role of HvgA in the 
crossing of the intestinal barrier. Fig. S2 shows that GBS ST-17 crosses the 
BBB upon oral inoculation. Table S1 describes the bacterial strains and plas-
mids used in this study. Table S2 describes the origin, the serotype, and the 
ST of GBS strains used in this study. Table S3 shows the list of primers used 
for genetic constructions and qRT-PCR. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20092594/DC1.
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